Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Khan Website

Javed Khan, M.D.

Selected Publications

1)  Orentas RJ, Nordlund J, He J, Sindiri S, Mackall C, Fry TJ, Khan J.
Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.
Front Oncol. 4: 134, 2014.
2)  Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J.
Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors.
Cancer Discov. 4: 216-31, 2014.
3)  Shah N, Wang J, Selich-Anderson J, Graham G, Siddiqui H, Li X, Khan J, Toretsky J.
PBX1 Is a Favorable Prognostic Biomarker as It Modulates 13-cis Retinoic Acid-Mediated Differentiation in Neuroblastoma.
Clin. Cancer Res. 2014.
4)  Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, Kim JS, Lopez Guerrero JA, Machado I, Wai DH, Picci P, Triche T, Horvai AE, Miettinen M, Wei JS, Catchpool D, Llombart-Bosch A, Waldman T, Khan J.
The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation.
PLoS Genet. 10: e1004475, 2014.
5)  Metaferia B, Wei JS, Song YK, Evangelista J, Aschenbach K, Johansson P, Wen X, Chen Q, Lee A, Hempel H, Gheeya JS, Getty S, Gomez R, Khan J.
Development of peptide nucleic acid probes for detection of the HER2 oncogene.
PLoS ONE. 8: e58870, 2013.
6)  Abdul-Karim R, Berkman BE, Wendler D, Rid A, Khan J, Badgett T, Hull SC.
Disclosure of incidental findings from next-generation sequencing in pediatric genomic research.
Pediatrics. 131: 564-71, 2013.
7)  Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI.
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Bioorg. Med. Chem. Lett. 23: 4398-403, 2013.
8)  Yeung CL, Ngo VN, Grohar PJ, Arnaldez FI, Asante A, Wan X, Khan J, Hewitt SM, Khanna C, Staudt LM, Helman LJ.
Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth.
Oncogene. 32: 5429-38, 2013.
9)  Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaqué Díez JP, Yu Y, Gutkind JS, Khan J.
Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma.
PLoS ONE. 8: e77731, 2013.
10)  Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.
Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534).
PLoS ONE. 8: e76551, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 7/30/2014.